Rifampin Capsules Recall: Failed Impurities May Cause Harm
Amerisource Health Services recalls Rifampin Capsules USP 300mg due to failed impurities and degradations. This medication is prescription-only and may pose health risks if used.
Recall notice
Failed Impurities/Degradations Specifications
Contact the company
What happened, in plain English
Amerisource Health Services is recalling Rifampin Capsules USP 300 mg (100 capsules per carton) because they failed impurities and degradations specifications. This could pose health risks if the medication is used as intended. Read more at govinfonow.com/recall/34174-rifampin-capsules-recall-failed-impurities-may-cause-harm.
Source Summary by GovInfoNow · govinfonow.com/recall/34174-rifampin-capsules-recall-failed-impurities-may-cause-harm · Updated August 18, 2026 · FDA enforcement record: FDA #D-0165-2023
Cite this page
“Rifampin Capsules Recall: Failed Impurities May Cause Harm.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/34174-rifampin-capsules-recall-failed-impurities-may-cause-harm. Based on FDA recall #D-0165-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0165-2023%22&limit=1).
Why it’s dangerous
The capsules failed impurities and degradations specifications, which means they may contain harmful substances or break down in a way that affects safety. This could lead to health risks if the medication is taken as directed.
Who’s affected
Prescription patients who have the specific lot number (1007805) of Rifampin Capsules USP 300 mg. Those using this medication for conditions like tuberculosis are most at risk.
How to tell if you have this one
Check for the carton NDC 60687-586-01 (Individual Dose NDC: 60687-586-11) with lot number 1007805. The capsules are prescription-only and expire December 31, 2023.
- Brand
Amerisource Health Services- Category
Drug
What to do — step by step
Check Product Details
Look for the carton NDC 60687-586-01 with lot number 1007805 on the packaging.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 21 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Amerisource Health Services recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0165-2023 (December 20, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0165-2023 to see it in context.
- Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.